NRG1 fusion-positive cancer

ASCO: Merus' gene-targeting cancer drug shrinks tumors. Will execs go it alone or partner?
Fierce Biotech
Tue, 06/7/22 - 10:16 am
ASCO 2022
Merus
zenocutuzumab
NRG1 fusion-positive cancer